Welcome to the Treating CD30+ Lymphoma Platform

Welcome, this website is intended for healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Webcast

New clips will be published regularly. Please sign up to the e-alert to keep informed of new webcast content being published to the site.

  • Treating CD30+ Lymphomas

    Welcome to the Treating CD30+ Lymphomas platform. Our expert faculty, Dr Anna Sureda and Dr Martin Hutchings discuss:

    A short introduction to brentuximab vedotin (Overview, antibody drug conjugates and mode of action)
    Phase I dose escalation study
    HL clinical data

    Phase II study results for relapsed/refractory HL post ASCT
    Long term survival analysis Phase II update (survival, response and safety)
    Transplant ineligible patients 

    sALCL clinical data

    Phase II study results in relapsed/refractory sALCL
    Long term survival analysis Phase II update (survival, response and safety)

    And the latest safety update

E-alert

Subscribe to our E-Alert to keep up to date with new webcast content published to the site.